

# Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

## Troy Laboratories Pty Ltd

Chemwatch Hazard Alert Code: 2

Chemwatch: 5401-54

Issue Date: 10/12/2021

Version No: 5.1

Print Date: 31/03/2025

Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

L.GHS.AUS.EN.E

### SECTION 1 Identification of the substance / mixture and of the company / undertaking

#### Product Identifier

<b>Product name</b>	Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses
<b>Chemical Name</b>	Not Applicable
<b>Synonyms</b>	APVMA number: 65030
<b>Chemical formula</b>	Not Applicable
<b>Other means of identification</b>	Not Available

#### Relevant identified uses of the substance or mixture and uses advised against

<b>Relevant identified uses</b>	Non-steroidal anti-inflammatory for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in horses. To be used as directed on product label
---------------------------------	---

#### Details of the manufacturer or supplier of the safety data sheet

<b>Registered company name</b>	Troy Laboratories Pty Ltd
<b>Address</b>	37 Glendenning Road Glendenning NSW 2761 Australia
<b>Telephone</b>	02 8808 3600
<b>Fax</b>	02 9677 9300
<b>Website</b>	<a href="http://www.Troylab.com.au">www.Troylab.com.au</a>
<b>Email</b>	admin@troylab.com.au

#### Emergency telephone number

<b>Association / Organisation</b>	Ixom Emergency Response Service
<b>Emergency telephone number(s)</b>	1800 033 111 (24 hours)
<b>Other emergency telephone number(s)</b>	Not Available

### SECTION 2 Hazards identification

#### Classification of the substance or mixture

<b>Poisons Schedule</b>	S4
<b>Classification <sup>[1]</sup></b>	Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Carcinogenicity Category 2, Reproductive Toxicity Category 2
<b>Legend:</b>	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

#### Label elements

<b>Hazard pictogram(s)</b>	
----------------------------	--

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

Signal word **Warning**

## Hazard statement(s)

<b>H315</b>	Causes skin irritation.
<b>H319</b>	Causes serious eye irritation.
<b>H351</b>	Suspected of causing cancer.
<b>H361d</b>	Suspected of damaging the unborn child.

## Precautionary statement(s) Prevention

<b>P201</b>	Obtain special instructions before use.
<b>P280</b>	Wear protective gloves, protective clothing, eye protection and face protection.
<b>P264</b>	Wash all exposed external body areas thoroughly after handling.

## Precautionary statement(s) Response

<b>P308+P313</b>	IF exposed or concerned: Get medical advice/ attention.
<b>P305+P351+P338</b>	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
<b>P337+P313</b>	If eye irritation persists: Get medical advice/attention.
<b>P302+P352</b>	IF ON SKIN: Wash with plenty of water.
<b>P332+P313</b>	If skin irritation occurs: Get medical advice/attention.
<b>P362+P364</b>	Take off contaminated clothing and wash it before reuse.

## Precautionary statement(s) Storage

<b>P405</b>	Store locked up.
-------------	------------------

## Precautionary statement(s) Disposal

<b>P501</b>	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
-------------	--

## SECTION 3 Composition / information on ingredients

## Substances

See section below for composition of Mixtures

## Mixtures

CAS No	%[weight]	Name
56-81-5	10-30	<u>glycerol</u>
71125-38-7	1-10	<u>meloxicam</u>
Not Available	balance	Ingredients determined not to be hazardous

**Legend:** 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; \* EU IOELVs available

## SECTION 4 First aid measures

## Description of first aid measures

<b>Eye Contact</b>	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> <li>▶ Wash out immediately with fresh running water.</li> <li>▶ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.</li> <li>▶ Seek medical attention without delay; if pain persists or recurs seek medical attention.</li> <li>▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
<b>Skin Contact</b>	<p>If skin contact occurs:</p> <ul style="list-style-type: none"> <li>▶ Immediately remove all contaminated clothing, including footwear.</li> <li>▶ Flush skin and hair with running water (and soap if available).</li> <li>▶ Seek medical attention in event of irritation.</li> </ul>
<b>Inhalation</b>	<ul style="list-style-type: none"> <li>▶ If fumes, aerosols or combustion products are inhaled remove from contaminated area.</li> <li>▶ Other measures are usually unnecessary.</li> </ul>
<b>Ingestion</b>	<ul style="list-style-type: none"> <li>▶ For advice, contact a Poisons Information Centre or a doctor at once.</li> <li>▶ Urgent hospital treatment is likely to be needed.</li> <li>▶ <b>If swallowed do NOT induce vomiting.</b></li> </ul>

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

- ▶ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.
- ▶ Observe the patient carefully.
- ▶ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.
- ▶ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.
- ▶ Transport to hospital or doctor without delay.

### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

## SECTION 5 Firefighting measures

### Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances.

In such an event consider:

- ▶ foam.
- ▶ dry chemical powder.
- ▶ carbon dioxide.

### Special hazards arising from the substrate or mixture

<b>Fire Incompatibility</b>	None known.
-----------------------------	-------------

### Advice for firefighters

<b>Fire Fighting</b>	<ul style="list-style-type: none"> <li>▶ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▶ Wear breathing apparatus plus protective gloves in the event of a fire.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water courses.</li> <li>▶ Use fire fighting procedures suitable for surrounding area.</li> <li>▶ <b>DO NOT</b> approach containers suspected to be hot.</li> <li>▶ Cool fire exposed containers with water spray from a protected location.</li> <li>▶ If safe to do so, remove containers from path of fire.</li> <li>▶ Equipment should be thoroughly decontaminated after use.</li> </ul>
<b>Fire/Explosion Hazard</b>	<ul style="list-style-type: none"> <li>▶ The material is not readily combustible under normal conditions.</li> <li>▶ However, it will break down under fire conditions and the organic component may burn.</li> <li>▶ Not considered to be a significant fire risk.</li> <li>▶ Heat may cause expansion or decomposition with violent rupture of containers.</li> <li>▶ Decomposes on heating and may produce toxic fumes of carbon monoxide (CO).</li> <li>▶ May emit acrid smoke.</li> </ul> <p>Decomposes on heating and produces toxic fumes of: carbon dioxide (CO<sub>2</sub>) acrolein other pyrolysis products typical of burning organic material.</p>
<b>HAZCHEM</b>	Not Applicable

## SECTION 6 Accidental release measures

### Personal precautions, protective equipment and emergency procedures

See section 8

### Environmental precautions

See section 12

### Methods and material for containment and cleaning up

<b>Minor Spills</b>	<ul style="list-style-type: none"> <li>▶ Clean up all spills immediately.</li> <li>▶ Avoid breathing vapours and contact with skin and eyes.</li> <li>▶ Control personal contact with the substance, by using protective equipment.</li> <li>▶ Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>▶ Wipe up.</li> <li>▶ Place in a suitable, labelled container for waste disposal.</li> </ul>
<b>Major Spills</b>	<ul style="list-style-type: none"> <li>▶ Clear area of personnel and move upwind.</li> <li>▶ Alert Fire Brigade and tell them location and nature of hazard.</li> <li>▶ May be violently or explosively reactive.</li> <li>▶ Wear full body protective clothing with breathing apparatus.</li> <li>▶ Prevent, by any means available, spillage from entering drains or water course.</li> <li>▶ Consider evacuation (or protect in place).</li> </ul>

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

- ▶ Stop leak if safe to do so.
- ▶ Contain spill with sand, earth or vermiculite.
- ▶ Collect recoverable product into labelled containers for recycling.
- ▶ Neutralise/decontaminate residue (see Section 13 for specific agent).
- ▶ Collect solid residues and seal in labelled drums for disposal.
- ▶ Wash area and prevent runoff into drains.
- ▶ After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
- ▶ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

## SECTION 7 Handling and storage

### Precautions for safe handling

<b>Safe handling</b>	<ul style="list-style-type: none"> <li>▶ Avoid all personal contact, including inhalation.</li> <li>▶ Wear protective clothing when risk of exposure occurs.</li> <li>▶ Use in a well-ventilated area.</li> <li>▶ Prevent concentration in hollows and sumps.</li> <li>▶ <b>DO NOT enter confined spaces until atmosphere has been checked.</b></li> <li>▶ <b>DO NOT allow material to contact humans, exposed food or food utensils.</b></li> <li>▶ Avoid contact with incompatible materials.</li> <li>▶ <b>When handling, DO NOT eat, drink or smoke.</b></li> <li>▶ Keep containers securely sealed when not in use.</li> <li>▶ Avoid physical damage to containers.</li> <li>▶ Always wash hands with soap and water after handling.</li> <li>▶ Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>▶ Use good occupational work practice.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> </ul>
<b>Other information</b>	<ul style="list-style-type: none"> <li>▶ Store in original containers.</li> <li>▶ Keep containers securely sealed.</li> <li>▶ Store in a cool, dry, well-ventilated area.</li> <li>▶ Store away from incompatible materials and foodstuff containers.</li> <li>▶ Protect containers against physical damage and check regularly for leaks.</li> <li>▶ Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

### Conditions for safe storage, including any incompatibilities

<b>Suitable container</b>	<ul style="list-style-type: none"> <li>▶ Packaging as recommended by manufacturer.</li> <li>▶ Check that containers are clearly labelled.</li> <li>▶ Tamper-proof containers.</li> <li>▶ Polyethylene or polypropylene containers.</li> <li>▶ Metal drum with sealed plastic liner.</li> <li>▶ Glass container is suitable for laboratory quantities</li> </ul>
<b>Storage incompatibility</b>	<ul style="list-style-type: none"> <li>▶ Avoid reaction with oxidising agents</li> <li>▶ Avoid strong acids, bases.</li> </ul>

## SECTION 8 Exposure controls / personal protection

### Control parameters

#### Occupational Exposure Limits (OEL)

#### INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	glycerol	Glycerin mist	10 mg/m3	Not Available	Not Available	(a) This value is for inhalable dust containing no asbestos and < 1% crystalline silica.

Ingredient	Original IDLH	Revised IDLH
glycerol	Not Available	Not Available
meloxicam	Not Available	Not Available

#### MATERIAL DATA

### Exposure controls

<b>Appropriate engineering controls</b>	<p>Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation.</p> <p>HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours.</p> <p>Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.</p>
---	--

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg. When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/ containment technology. Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies. Barrier/ containment technology and direct coupling (totally enclosed processes that create a barrier between the equipment and the room) typically use double or split butterfly valves and hybrid unidirectional airflow/ local exhaust ventilation solutions (e.g. powder containment booths). Glove bags, isolator glove box systems are optional. HEPA filtration of exhaust from dry product handling areas is required. Fume-hoods and other open-face containment devices are acceptable when face velocities of at least 1 m/s (200 feet/minute) are achieved. Partitions, barriers, and other partial containment technologies are required to prevent migration of the material to uncontrolled areas. For non-routine emergencies maximum local and general exhaust are necessary. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, etc. evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2.5 m/s (200-500 f/min.) for extraction of gases discharged 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated: Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated.

The following protective devices are recommended where exposures exceed the recommended exposure control guidelines by factors of:

- 10; high efficiency particulate (HEPA) filters or cartridges
- 10-25; loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator.
- 25-50; a full face-piece negative pressure respirator with HEPA filters
- 50-100; tight-fitting, full face-piece HEPA PAPR
- 100-1000; a hood-shroud HEPA PAPR or full face-piece supplied air respirator operated in pressure demand or other positive pressure mode.

#### Individual protection measures, such as personal protective equipment



#### Eye and face protection

When handling very small quantities of the material eye protection may not be required. For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- ▶ Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- ▶ Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.
- ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

#### Skin protection

See Hand protection below

#### Hands/feet protection

- ▶ Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference.
- ▶ Double gloving should be considered.
- ▶ PVC gloves.
- ▶ Change gloves frequently and when contaminated, punctured or torn.
- ▶ Wash hands immediately after removing gloves.
- ▶ Protective shoe covers. [AS/NZS 2210]
- ▶ Head covering.

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

<b>Body protection</b>	See Other protection below
<b>Other protection</b>	<ul style="list-style-type: none"> <li>▶ For quantities up to 500 grams a laboratory coat may be suitable.</li> <li>▶ For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.</li> <li>▶ For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.</li> <li>▶ For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.</li> <li>▶ Eye wash unit.</li> <li>▶ Ensure there is ready access to an emergency shower.</li> <li>▶ For Emergencies: Vinyl suit</li> </ul>

**Recommended material(s)****GLOVE SELECTION INDEX**

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the **computer-generated** selection:

Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

Material	CPI
BUTYL	C
NATURAL RUBBER	C
NATURAL+NEOPRENE	C
NEOPRENE	C
NITRILE	C
PVA	C
VITON	C

\* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

**NOTE:** As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

**Ansell Glove Selection**

Glove — <i>In order of recommendation</i>
AlphaTec 02-100
AlphaTec® 15-554
AlphaTec® Solvex® 37-185
TouchNTuff® DermaShield™ 73-701
AlphaTec® 38-612
AlphaTec® 53-001
AlphaTec® 58-005
AlphaTec® 58-008
AlphaTec® 58-530B
AlphaTec® 58-530W

The suggested gloves for use should be confirmed with the glove supplier.

**Respiratory protection**

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO<sub>2</sub>), G = Agricultural chemicals, K = Ammonia(NH<sub>3</sub>), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- ▶ Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- ▶ The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- ▶ Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

**SECTION 9 Physical and chemical properties****Information on basic physical and chemical properties**

<b>Appearance</b>	Opaque yellow liquid; mixes with water.		
<b>Physical state</b>	Liquid	<b>Relative density (Water = 1)</b>	1.14
<b>Odour</b>	Not Available	<b>Partition coefficient n-octanol / water</b>	Not Available

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

<b>Odour threshold</b>	Not Available	<b>Auto-ignition temperature (°C)</b>	Not Applicable
<b>pH (as supplied)</b>	3.5-4.5	<b>Decomposition temperature (°C)</b>	Not Available
<b>Melting point / freezing point (°C)</b>	Not Available	<b>Viscosity (cSt)</b>	Not Available
<b>Initial boiling point and boiling range (°C)</b>	Not Available	<b>Molecular weight (g/mol)</b>	Not Applicable
<b>Flash point (°C)</b>	Not Applicable	<b>Taste</b>	Not Available
<b>Evaporation rate</b>	Not Available	<b>Explosive properties</b>	Not Available
<b>Flammability</b>	Not Applicable	<b>Oxidising properties</b>	Not Available
<b>Upper Explosive Limit (%)</b>	Not Applicable	<b>Surface Tension (dyn/cm or mN/m)</b>	Not Available
<b>Lower Explosive Limit (%)</b>	Not Applicable	<b>Volatile Component (%vol)</b>	Not Available
<b>Vapour pressure (kPa)</b>	Not Available	<b>Gas group</b>	Not Available
<b>Solubility in water</b>	Miscible	<b>pH as a solution (1%)</b>	Not Available
<b>Vapour density (Air = 1)</b>	Not Available	<b>VOC g/L</b>	Not Available
<b>Heat of Combustion (kJ/g)</b>	Not Available	<b>Ignition Distance (cm)</b>	Not Available
<b>Flame Height (cm)</b>	Not Available	<b>Flame Duration (s)</b>	Not Available
<b>Enclosed Space Ignition Time Equivalent (s/m3)</b>	Not Available	<b>Enclosed Space Ignition Deflagration Density (g/m3)</b>	Not Available

## SECTION 10 Stability and reactivity

<b>Reactivity</b>	See section 7
<b>Chemical stability</b>	<ul style="list-style-type: none"> <li>▶ Unstable in the presence of incompatible materials.</li> <li>▶ Product is considered stable.</li> <li>▶ Hazardous polymerisation will not occur.</li> </ul>
<b>Possibility of hazardous reactions</b>	See section 7
<b>Conditions to avoid</b>	See section 7
<b>Incompatible materials</b>	See section 7
<b>Hazardous decomposition products</b>	See section 5

## SECTION 11 Toxicological information

## Information on toxicological effects

<b>a) Acute Toxicity</b>	Based on available data, the classification criteria are not met.
<b>b) Skin Irritation/Corrosion</b>	There is sufficient evidence to classify this material as skin corrosive or irritating.
<b>c) Serious Eye Damage/Irritation</b>	There is sufficient evidence to classify this material as eye damaging or irritating
<b>d) Respiratory or Skin sensitisation</b>	Based on available data, the classification criteria are not met.
<b>e) Mutagenicity</b>	Based on available data, the classification criteria are not met.
<b>f) Carcinogenicity</b>	There is sufficient evidence to classify this material as carcinogenic
<b>g) Reproductivity</b>	There is sufficient evidence to classify this material as toxic to reproductivity
<b>h) STOT - Single Exposure</b>	Based on available data, the classification criteria are not met.
<b>i) STOT - Repeated Exposure</b>	Based on available data, the classification criteria are not met.
<b>j) Aspiration Hazard</b>	Based on available data, the classification criteria are not met.

<b>Inhaled</b>	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
<b>Ingestion</b>	The material has <b>NOT</b> been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health).

Continued...



## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

	Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.
<b>Skin Contact</b>	<p>Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p> <p>The material may accentuate any pre-existing dermatitis condition</p> <p>Open cuts, abraded or irritated skin should not be exposed to this material</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p>
<b>Eye</b>	<p>Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.</p> <p>Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p>
<b>Chronic</b>	<p>Exposure to the material may cause concerns for humans owing to possible developmental toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects.</p> <p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p>

<b>Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses</b>	<b>TOXICITY</b>	<b>IRRITATION</b>
	Not Available	Not Available
<b>glycerol</b>	<b>TOXICITY</b>	<b>IRRITATION</b>
	Dermal (Guinea Pig) LD50: 58500 mg/kg <sup>[1]</sup>	Eye (Rodent - rabbit): 500mg/24H - Mild
	Inhalation (Rat) LC50: >5.85 mg/L4h <sup>[1]</sup>	Eye: no adverse effect observed (not irritating) <sup>[1]</sup>
	Oral (Mouse) LD50; 4090 mg/kg <sup>[2]</sup>	Skin (Rodent - rabbit): 500mg/24H - Mild
		Skin: no adverse effect observed (not irritating) <sup>[1]</sup>
<b>meloxicam</b>	<b>TOXICITY</b>	<b>IRRITATION</b>
	Oral (Rabbit) LD50; 320 mg/kg <sup>[2]</sup>	Not Available
<b>Legend:</b>	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances	

<b>GLYCEROL</b>	<p>Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.</p> <p>For glycerol:</p> <p><b>Acute toxicity:</b> Glycerol is of a low order of acute oral and dermal toxicity with LD50 values in excess of 4000 mg/kg bw. At very high dose levels, the signs of toxicity include tremor and hyperaemia of the gastro-intestinal -tract. Skin and eye irritation studies indicate that glycerol has low potential to irritate the skin and the eye. The available human and animal data, together with the very widespread potential for exposure and the absence of case reports of sensitisation, indicate that glycerol is not a skin sensitiser.</p> <p><b>Repeat dose toxicity:</b> Repeated oral exposure to glycerol does not induce adverse effects other than local irritation of the gastro-intestinal tract. The overall NOEL after prolonged treatment with glycerol is 10,000 mg/kg bw/day (20% in diet). At this dose level no systemic or local effects were observed. For inhalation exposure to aerosols, the NOAEC for local irritant effects to the upper respiratory tract is 165 mg/m<sup>3</sup> and 662 mg/m<sup>3</sup> for systemic effects.</p> <p><b>Genotoxicity:</b> Glycerol is free from structural alerts, which raise concern for mutagenicity. Glycerol does not induce gene mutations in bacterial strains, chromosomal effects in mammalian cells or primary DNA damage <i>in vitro</i>. Results of a limited gene mutation test in mammalian cells were of uncertain biological relevance. <i>In vivo</i>, glycerol produced no statistically significant effect in a chromosome aberrations and dominant lethal study. However, the limited details provided and the absence of a positive control, prevent any reliable conclusions to be drawn from the <i>in vivo</i> data. Overall, glycerol is not considered to possess genotoxic potential.</p>
-----------------	--



## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

**Carcinogenicity:** The experimental data from a limited 2 year dietary study in the rat does not provide any basis for concerns in relation to carcinogenicity. Data from non-guideline studies designed to investigate tumour promotion activity in male mice suggest that oral administration of glycerol up to 20 weeks had a weak promotion effect on the incidence of tumour formation.

**Reproductive and developmental toxicity:** No effects on fertility and reproductive performance were observed in a two generation study with glycerol administered by gavage (NOAEL 2000 mg/kg bw/day). No maternal toxicity or teratogenic effects were seen in the rat, mouse or rabbit at the highest dose levels tested in a guideline comparable teratogenicity study (NOEL 1180 mg/kg bw/day).

## MELOXICAM

Carcinogenicity: No carcinogenic effect of meloxicam was observed in rats given oral doses up to 0.8 mg/kg/day (approximately 0.4-fold the human dose at 15 mg/day for a 50 kg adult based on body surface area conversion) for 104 weeks or in mice given oral doses up to 8.0 mg/kg/day (approximately 2.2-fold the human dose, as noted above) for 99 weeks. Reproductive Toxicity: Meloxicam did not impair male and female fertility in rats at oral doses up to 9 and 5 mg/kg/day, respectively (4.9-fold and 2.5-fold the human dose, as noted above). However, an increased incidence of embryoletality at oral doses  $\geq$  1 mg/kg/day (0.5-fold the human dose, as noted above) was observed in rats when dams were given meloxicam 2 weeks prior to mating and during early embryonic development. Teratogenicity: Pregnancy Category C: Meloxicam caused an increased incidence of septal defect of the heart, a rare event, at an oral dose of 60 mg/kg/day (64.5-fold the human dose at 15 mg/day for a 50 kg adult based on body surface area conversion) and embryoletality at oral doses  $\geq$  5 mg/kg/day (5.4-fold the human dose, as noted above) when rabbits were treated throughout organogenesis. Meloxicam was not teratogenic in rats up to an oral dose of 4 mg/kg/day (approximately 2.2-fold the human dose, as noted above) throughout organogenesis. An increased incidence of stillbirths was observed when rats were given oral doses  $\geq$  1 mg/kg/day throughout organogenesis. Meloxicam crosses the placental barrier. There are no adequate and well-controlled studies in pregnant women. Mutagenicity: Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with human lymphocytes and an in vivo micronucleus test in mouse bone marrow. \* Apotex SDS

Accumulated studies have proved that non-steroidal anti-inflammatory drugs (NSAIDs) which block inflammation by their actions on arachidonic acid (AA) metabolism have a potential role in cancer chemotherapy and chemoprevention.

There is a general acceptance that NSAIDs induce colon cancer in humans. One suggested reason is that the balance between COX and lipoxygenase (LOX) activity determines tumorigenesis critically. Under low COX activity, arachidonic acid released from cell membranes in response to external stimuli is preferentially metabolized by LOX enzymes. The oxygenated lipids (metabolites) produced by LOXs initiate subsequent biological reactions, activate cellular signaling mechanisms through specific cell surface receptors, or are further metabolized into potent lipid mediators.

There is evidence that a 15-LOX metabolite 13S-HPODE (13S-hydroperoxyoctadecaenoic acid) generated from linoleic acid induces apoptosis in colon cancer.

Ingestion of aspirin or other NSAIDs may elicit respiratory, nasal, and gastrointestinal symptoms, as well as dermal changes in a subset of patients with asthma. The sensitivity to cyclooxygenase (COX) inhibitors has led to the hypothesis that NSAIDs may be causing upregulation of the 5-lipoxygenase pathway and its attendant products, the leukotrienes, in these patients. It has been shown increase in urinary leukotriene E 4 (LTE4) after aspirin ingestion or inhalation of lysine-aspirin in aspirin-sensitive patients with asthma. It has also been demonstrated that pharmacologic blockade at the level of the cysteinyl leukotriene receptor(s) can blunt the bronchospastic response to aspirin. Cysteinyl leukotrienes are potent bronchoconstrictors, induce mucus secretion, and increase vascular permeability. Importantly, inhibition of 5-lipoxygenase blocks not only the respiratory but also the gastrointestinal and dermal reactions to aspirin in aspirin-sensitive patients with asthma. Although these results establish the importance of 5-lipoxygenase products in mediating reactions to aspirin, the cellular source and mechanism of release of these mediators remain unclear.

Mast cells, which are a known source of leukotrienes, are activated in the nasal response to aspirin as demonstrated by the detection of nasal tryptase after aspirin challenge. Tryptase is an enzyme specific to mast cells and is an indicator of mast cell activation. Cysteinyl leukotrienes and histamine, which can be produced by mast cells, were detected as well. The occurrence of nasal symptoms, as well as activation of mast cells, in response to aspirin was blocked by zileuton, an inhibitor of 5-lipoxygenase. This confirms that 5-lipoxygenase products are critical to the development of aspirin-induced asthma (ASA-induced) reactions in the nose. It also suggests that 5-lipoxygenase products may have a role in the activation of mast cells during this reaction.

Acute Toxicity	✗	Carcinogenicity	✔
Skin Irritation/Corrosion	✔	Reproductivity	✔
Serious Eye Damage/Irritation	✔	STOT - Single Exposure	✗
Respiratory or Skin sensitisation	✗	STOT - Repeated Exposure	✗
Mutagenicity	✗	Aspiration Hazard	✗

**Legend:** ✗ – Data either not available or does not fill the criteria for classification  
✔ – Data available to make classification

## SECTION 12 Ecological information

## Toxicity

Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
glycerol	Endpoint	Test Duration (hr)	Species	Value	Source
	LC50	96h	Fish	>11mg/L	2
	EC0(ECx)	24h	Crustacea	>500mg/l	1

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

meloxicam	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	144h	Fish	0.1mg/L	4
<b>Legend:</b>	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data				

**DO NOT** discharge into sewer or waterways.

## Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
glycerol	LOW	LOW

## Bioaccumulative potential

Ingredient	Bioaccumulation
glycerol	LOW (LogKOW = -1.76)

## Mobility in soil

Ingredient	Mobility
glycerol	HIGH (Log KOC = 1)

## SECTION 13 Disposal considerations

## Waste treatment methods

<b>Product / Packaging disposal</b>	<ul style="list-style-type: none"> <li>▶ Containers may still present a chemical hazard/ danger when empty.</li> <li>▶ Return to supplier for reuse/ recycling if possible.</li> </ul> Otherwise: <ul style="list-style-type: none"> <li>▶ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.</li> <li>▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.</li> <li>▶ Recycle wherever possible or consult manufacturer for recycling options.</li> <li>▶ Consult State Land Waste Authority for disposal.</li> <li>▶ Bury or incinerate residue at an approved site.</li> <li>▶ Recycle containers if possible, or dispose of in an authorised landfill.</li> </ul>
-------------------------------------	---

## SECTION 14 Transport information

## Labels Required

<b>Marine Pollutant</b>	NO
<b>HAZCHEM</b>	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

## 14.7. Maritime transport in bulk according to IMO instruments

## 14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

## 14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
glycerol	Not Available
meloxicam	Not Available

## 14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
glycerol	Not Available

Continued...

## Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses

Product name	Ship Type
meloxicam	Not Available

## SECTION 15 Regulatory information

## Safety, health and environmental regulations / legislation specific for the substance or mixture

## glycerol is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

## meloxicam is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

FEI Equine Prohibited Substances List - Controlled Medication

FEI Equine Prohibited Substances List (EPLS)

## Additional Regulatory Information

Not Applicable

## National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (meloxicam)
Canada - DSL	No (meloxicam)
Canada - NDSL	No (glycerol; meloxicam)
China - IECSC	No (meloxicam)
Europe - EINEC / ELINCS / NLP	No (meloxicam)
Japan - ENCS	No (meloxicam)
Korea - KECI	No (meloxicam)
New Zealand - NZIoC	Yes
Philippines - PICCS	No (meloxicam)
USA - TSCA	TSCA Inventory 'Active' substance(s) (glycerol); No (meloxicam)
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	No (meloxicam)
<b>Legend:</b>	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

## SECTION 16 Other information

<b>Revision Date</b>	10/12/2021
<b>Initial Date</b>	16/05/2020

## SDS Version Summary

Version	Date of Update	Sections Updated
4.1	20/08/2021	Classification change due to full database hazard calculation/update.
5.1	10/12/2021	Classification change due to full database hazard calculation/update.

## Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Continued...

**Ilium Meloxicam 30 Anti-Inflammatory Oral Suspension for Horses****Definitions and abbreviations**

- PC - TWA: Permissible Concentration-Time Weighted Average
- PC - STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ACGIH: American Conference of Governmental Industrial Hygienists
- STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit,
- IDLH: Immediately Dangerous to Life or Health Concentrations
- ES: Exposure Standard
- OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- LOAEL: Lowest Observed Adverse Effect Level
- TLV: Threshold Limit Value
- LOD: Limit Of Detection
- OTV: Odour Threshold Value
- BCF: BioConcentration Factors
- BEI: Biological Exposure Index
- DNEL: Derived No-Effect Level
- PNEC: Predicted no-effect concentration
- MARPOL: International Convention for the Prevention of Pollution from Ships
- IMSBC: International Maritime Solid Bulk Cargoes Code
- IGC: International Gas Carrier Code
- IBC: International Bulk Chemical Code
  
- AIIC: Australian Inventory of Industrial Chemicals
- DSL: Domestic Substances List
- NDSL: Non-Domestic Substances List
- IECSC: Inventory of Existing Chemical Substance in China
- EINECS: European INventory of Existing Commercial chemical Substances
- ELINCS: European List of Notified Chemical Substances
- NLP: No-Longer Polymers
- ENCS: Existing and New Chemical Substances Inventory
- KECI: Korea Existing Chemicals Inventory
- NZIoC: New Zealand Inventory of Chemicals
- PICCS: Philippine Inventory of Chemicals and Chemical Substances
- TSCA: Toxic Substances Control Act
- TCSI: Taiwan Chemical Substance Inventory
- INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.